治疗性血浆置换与接受连续肾脏替代治疗的儿童及年轻成人血小板减少患者主要不良肾脏事件改善相关
本研究为回顾性队列,纳入2014至2020年两所四级儿科医院接受CKRT的≤26岁患者,定义CKRT起始时血小板≤100,000 cell/mm3为血小板减少,主要终点为90天主要不良肾脏事件(MAKE90,含死亡、需肾脏替代治疗或eGFR较基线下降≥25%)。413例中284例(68.8%)存在血小板减少,MAKE90发生率为69.0%,41.5%接受TPE。多因素分析(OR 0.35;95%CI 0.20-0.60)和倾向评分加权(校正OR 0.31;95%CI 0.16-0.59)均显示TPE使用与MAKE90降低独立相关。作者认为在此亚组患者中数据提示TPE降低MAKE90的获益。
要点
- 在CKRT起始时血小板≤100,000 cell/mm3的≤26岁患者中,MAKE90发生率为69.0%。
- 284例血小板减少患者中41.5%接受了TPE。
- 多因素分析显示TPE与MAKE90降低独立相关(OR 0.35;95%CI 0.20-0.60)。
- 倾向评分加权分析同样显示TPE与MAKE90降低相关(校正OR 0.31;95%CI 0.16-0.59)。
- MAKE90定义为死亡、需肾脏替代治疗或eGFR较基线下降≥25%的复合终点。
适用人群与场景
- 2014至2020年间在两所大型四级儿科医院接受CKRT、年龄≤26岁的患者。
- 分析人群为CKRT起始时血小板计数≤100,000 cell/mm3者,排除血栓性血小板减少性紫癜(n=6)和慢性疾病所致血小板减少(n=2)的患者。
- 284例血小板减少患者中51%为女性,中位年龄69个月(四分位距13-128个月)。
诊断标准与关键阈值
- 血小板减少定义为CKRT起始时血小板计数≤100,000 cell/mm3。
- MAKE90定义为CKRT起始后90天内死亡、需肾脏替代治疗或eGFR较基线下降≥25%的复合终点。
研究设计与关键结果
- 研究类型为回顾性队列,纳入413例接受CKRT的≤26岁患者,其中284例(68.8%)在CKRT起始时存在血小板减少。
- 血小板减少患者中MAKE90发生率为69.0%,41.5%接受了TPE。
- 多因素logistic回归显示TPE使用与MAKE90降低独立相关(OR 0.35;95%CI 0.20-0.60)。
- 倾向评分加权分析显示TPE使用与MAKE90降低相关(校正OR 0.31;95%CI 0.16-0.59)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在CKRT起始时血小板减少的儿童及年轻成人中,数据提示TPE可降低MAKE90发生率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Therapeutic plasma exchange (TPE) has been shown to improve organ dysfunction and survival in patients with thrombotic microangiopathy and thrombocytopenia associated with multiple organ failure. There are no known therapies for the prevention of major adverse kidney events after continuous kidney replacement therapy (CKRT). The primary objective of this study was to evaluate the effect of TPE on the rate of adverse kidney events in children and young adults with thrombocytopenia at the time of CKRT initiation.
DESIGN: Retrospective cohort.
SETTING: Two large quaternary care pediatric hospitals.
PATIENTS: All patients less than or equal to 26 years old who received CKRT between 2014 and 2020.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We defined thrombocytopenia as a platelet count less than or equal to 100,000 (cell/mm3) at the time of CKRT initiation. We ascertained major adverse kidney events at 90 days (MAKE90) after CKRT initiation as the composite of death, need for kidney replacement therapy, or a greater than or equal to 25% decline in estimated glomerular filtration rate from baseline. We performed multivariable logistic regression and propensity score weighting to analyze the relationship between the use of TPE and MAKE90. After excluding patients with a diagnosis of thrombotic thrombocytopenia purpura and atypical hemolytic uremic syndrome (n = 6) and with thrombocytopenia due to a chronic illness (n = 2), 284 of 413 total patients (68.8%) had thrombocytopenia at CKRT initiation (51% female). Of the patients with thrombocytopenia, the median (interquartile range) age was 69 months (13-128 mo). MAKE90 occurred in 69.0% and 41.5% received TPE. The use of TPE was independently associated with reduced MAKE90 by multivariable analysis (odds ratio [OR], 0.35; 95% CI, 0.20-0.60) and by propensity score weighting (adjusted OR, 0.31; 95% CI, 0.16-0.59).
CONCLUSIONS: Thrombocytopenia is common in children and young adults at CKRT initiation and is associated with increased MAKE90. In this subset of patients, our data show benefit of TPE in reducing the rate of MAKE90.
参考来源
- Fuhrman DY, Thadani S, Hanson C, et al. Therapeutic Plasma Exchange Is Associated With Improved Major Adverse Kidney Events in Children and Young Adults With Thrombocytopenia at the Time of Continuous Kidney Replacement Therapy Initiation. Crit Care Explor. 2023. PMID: 37066071. doi:10.1097/CCE.0000000000000891
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。